Growth Metrics

Incyte (INCY) Net Margin (2010 - 2026)

Incyte posted quarterly Net Margin of 23.83% for Q1 2026, up 881.0% year-on-year from 2.43% in Q1 2025, and up 20.0% on a QoQ basis from 19.86% in Q4 2025.

Incyte (INCY) has 17 years of Net Margin data on file, last reported at 23.83% in Q1 2026.

  • For the quarter ending Q1 2026, Net Margin rose 881.0% year-over-year to 23.83%; the trailing twelve-month figure through Mar 2026 stood at 26.71% (up 2623.0% YoY), and the FY2025 full-year result was 25.03%, up 2426.0% from the prior year.
  • Net Margin for Q1 2026 stood at 23.83%, up from 19.86% in the prior quarter.
  • Across five years, Net Margin topped out at 33.32% in Q2 2025 and bottomed at 42.6% in Q2 2024.
  • The 5-year median for Net Margin is 17.71% (2022), against an average of 13.43%.
  • The widest annual swing landed in 2024, when Net Margin slumped 6392 bps; it then soared 7591 bps in 2025.
  • A 5-year view of Net Margin shows it stood at 3.07% in 2022, then soared by 546 bps to 19.84% in 2023, then retreated by 14 bps to 17.07% in 2024, then gained by 16 bps to 19.86% in 2025, then rose by 20 bps to 23.83% in 2026.
  • The last three Net Margin figures came in at 23.83% (Q1 2026), 19.86% (Q4 2025), and 31.05% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 0.82%
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 34.53%
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 20.17%
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 17.65%
10 Incyte 19.28 Bn 15.27 Bn 1.17 Bn 23.83%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 23.83%
Dec 31, 2025 19.86%
Sep 30, 2025 31.05%
Jun 30, 2025 33.32%
Mar 31, 2025 15.03%
Dec 31, 2024 17.07%
Sep 30, 2024 9.36%
Jun 30, 2024 -42.60%
Mar 31, 2024 19.25%
Dec 31, 2023 19.84%
Sep 30, 2023 18.64%
Jun 30, 2023 21.32%
Mar 31, 2023 2.68%
Dec 31, 2022 3.07%
Sep 30, 2022 13.70%
Jun 30, 2022 17.71%
Mar 31, 2022 5.18%
Dec 31, 2021 65.35%
Sep 30, 2021 22.35%
Jun 30, 2021 21.18%
Mar 31, 2021 8.85%
Dec 31, 2020 18.98%
Sep 30, 2020 -2.45%
Jun 30, 2020 42.19%
Mar 31, 2020 -126.76%
Dec 31, 2019 19.16%
Sep 30, 2019 23.26%
Jun 30, 2019 19.87%
Mar 31, 2019 20.55%
Dec 31, 2018 13.07%
Sep 30, 2018 6.49%
Jun 30, 2018 10.05%
Mar 31, 2018 -10.76%
Dec 31, 2017 -33.69%
Sep 30, 2017 9.45%
Jun 30, 2017 -3.82%
Mar 31, 2017 -48.71%
Dec 31, 2016 2.72%
Sep 30, 2016 13.69%
Jun 30, 2016 13.98%
Mar 31, 2016 9.13%
Dec 31, 2015 22.62%
Sep 30, 2015 -21.10%
Jun 30, 2015 5.70%
Mar 31, 2015 -11.53%
Dec 31, 2014 -29.80%
Sep 30, 2014 29.92%
Jun 30, 2014 -37.03%
Mar 31, 2014 -37.82%
Dec 31, 2013 -44.16%
Sep 30, 2013 -25.89%
Jun 30, 2013 -2.53%
Mar 31, 2013 -22.05%
Dec 31, 2012 16.50%
Sep 30, 2012 -35.89%
Jun 30, 2012 4.66%
Mar 31, 2012 -125.56%
Dec 31, 2011 -190.66%
Sep 30, 2011 -316.28%
Jun 30, 2011 -308.55%
Mar 31, 2011 -82.92%
Dec 31, 2010 37.90%
Sep 30, 2010 -187.89%
Jun 30, 2010 6.11%
Mar 31, 2010 -206.67%